Vertex Pharmaceuticals Incorporated (LON:0QZU)
406.24
-1.23 (-0.30%)
At close: Oct 3, 2025
Vertex Pharmaceuticals Revenue
Vertex Pharmaceuticals had revenue of $2.96B USD in the quarter ending June 30, 2025, with 12.06% growth. This brings the company's revenue in the last twelve months to $11.42B, up 10.46% year-over-year. In the year 2024, Vertex Pharmaceuticals had annual revenue of $11.02B with 11.66% growth.
Revenue (ttm)
$11.42B
Revenue Growth
+10.46%
P/S Ratio
9.21
Revenue / Employee
$1.87M
Employees
6,100
Market Cap
76.73B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 11.02B | 1.15B | 11.66% |
Dec 31, 2023 | 9.87B | 938.50M | 10.51% |
Dec 31, 2022 | 8.93B | 1.36B | 17.91% |
Dec 31, 2021 | 7.57B | 1.37B | 22.06% |
Dec 31, 2020 | 6.21B | 2.04B | 49.08% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Vertex Pharmaceuticals News
- 3 days ago - Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider - Nasdaq
- 3 days ago - Vertex Pharmaceuticals (VRTX) Receives Raised Price Target from Citigroup | VRTX Stock News - GuruFocus
- 3 days ago - Final Trades: ServiceNow, Vertex Pharmaceuticals and the IJR - CNBC
- 9 days ago - Vertex (VRTX) Is Considered a Good Investment by Brokers: Is That True? - Nasdaq
- 9 days ago - Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet - Benzinga
- 10 days ago - Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note - Nasdaq
- 10 days ago - Vertex Pharmaceuticals: Trikafta And Alyftrek Cement Market Leadership - Seeking Alpha
- 10 days ago - Vertex (VRTX) Initiates Phase 2 Study for ADPKD Treatment - GuruFocus